08.08.2011 • News

Arch Chemicals Q2 Profit Falls

Biocides company Arch Chemicals, which is in $1.4 billion cash deal to be acquired by Lonza reported that its second-quarter earnings from continuing operations was $37.4 million or $1.47 per share, lower than prior year's $43.5 million or $1.73 per share.

The latest quarter results included a charge of $0.3 million or $0.01 per share, for relocation costs incurred in conjunction with the previously announced research and development consolidation.

Excluding this item, earnings from continuing operations for 2011 were $37.7 million or $1.48 per share.

Analysts polled by Thomson Reuters expected earnings of $1.82 per share for the quarter. Analysts' estimates typically exclude special items.
The company noted that the second-quarter earnings were significantly impacted by lower-than-expected results from the HTH water products business, principally due to timing.

Sales for the second quarter were $443.8 million, compared to $441.4 million for the second quarter of 2010.

 

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read